v3.22.2.2
Consolidated Statements of (Loss) Income and Comprehensive (Loss) Income (Unaudited) - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Revenues $ 33,234 $ 21,761 $ 95,733 $ 74,504
Cost of products sold 26,519 16,653 74,414 55,151
Gross profit 6,715 5,108 21,319 19,353
Operating expenses:        
Research and development 1,896 1,723 5,425 5,223
Selling, general and administrative 5,405 4,164 15,982 12,866
Total operating expenses 7,301 5,887 21,407 18,089
Operating (loss) income (586) (779) (88) 1,264
Other (income) expense:        
Interest and financing expense 272 53 583 164
Miscellaneous 526 54 605 88
Total other (income) expense 254 1 22 (76)
(Loss) income before income taxes (332) (778) (66) 1,188
Income tax (benefit) provision (90) (175) (171) 290
Net (loss) income (242) (603) 105 898
Net (loss) income attributable to non-controlling interest (3) (18) 0 1
Net (loss) income attributable to Ultralife Corporation (239) (585) 105 897
Other comprehensive loss:        
Foreign currency translation adjustments (1,691) (233) (3,189) (37)
Comprehensive (loss) income attributable to Ultralife Corporation $ (1,930) $ (818) $ (3,084) $ 860
Net (loss) income per share attributable to Ultralife common stockholders – basic (in dollars per share) $ 0.03 $ 0.05 $ 0.02 $ 0.09
Net (loss) income per share attributable to Ultralife common stockholders – diluted (in dollars per share) $ 0.03 $ 0.05 $ 0.02 $ 0.09
Weighted average shares outstanding – basic (in shares) 16,133 16,065 16,122 16,020
Potential common shares (in shares) 0 0 22 180
Weighted average shares outstanding - diluted (in shares) 16,133 16,065 16,144 16,200